Last updated: March 14, 2026
What is the Drug Identified by NDC 52427-0382?
NDC 52427-0382 corresponds to Ocrevus (ocrelizumab), a monoclonal antibody used primarily to treat multiple sclerosis (MS). It is approved for relapsing forms of MS and primary progressive MS. Ocrevus is administered via intravenous infusion, typically every six months after initial dosing.
Market Overview
Current Market Size
The global multiple sclerosis drug market was valued at approximately USD 26.5 billion in 2022. Ocrevus holds about 12% market share, making it one of the top-selling MS therapies. Its sales revenue in 2022 was approximately USD 4.2 billion, according to IQVIA data.
Major Competitors
| Drug Name |
Mechanism of Action |
Licensed Indications |
2022 Sales (USD billions) |
Market Share |
| Ocrevus (Ocrelizumab) |
B-cell depleting monoclonal antibody |
Relapsing and primary progressive MS |
4.2 |
12% |
| Tecfidera (Dimethyl fumarate) |
Anti-inflammatory |
Relapsing-remitting MS |
3.0 |
9% |
| Mavenclad (Cladribine) |
Purine analog |
Relapsing and primary progressive MS |
0.9 |
3% |
| Lemtrada (Alemtuzumab) |
Monoclonal antibody |
Relapsing-remitting MS |
0.8 |
3% |
Key Drivers of Market Growth
- Rising prevalence of MS globally, estimated at 2.8 million cases in 2022.
- Aging populations with increased susceptibility.
- Expanding approved indications, including primary progressive MS.
- Continued innovation in B-cell depleting therapies.
Challenges
- High drug costs limiting access.
- Safety concerns, including infusion reactions and infections.
- Competition from newer oral therapies with similar efficacy.
Price Projection Analysis
Current Pricing Dynamics
In the U.S., the average wholesale price (AWP) for Ocrevus is approximately USD 65,000 per 300 mg vial. Patients typically receive two doses initially, then a 600 mg infusion every six months, equating to roughly USD 130,000 annually per patient.
Revenue Forecasts (2023-2027)
| Year |
Estimated Market Penetration |
Projected Revenue |
Assumptions |
| 2023 |
15% of total MS market |
USD 4.7 billion |
Stable market share, no new competitors |
| 2024 |
17% |
USD 5.4 billion |
Slight increase in patient access |
| 2025 |
20% |
USD 6.2 billion |
Expansion to new markets, approvals |
| 2026 |
22% |
USD 6.8 billion |
Increased prescribing, price adjustments |
| 2027 |
25% |
USD 8.0 billion |
Adoption of biosimilars minimally impacting sales |
Biosimilar Impact
Biosimilar versions of ocrelizumab could enter the market by 2026, potentially reducing U.S. prices by 20-30%. This could bring peak prices down to USD 45,000-50,000 per year per patient, affecting revenue projections post-2026.
Pricing Strategies and Reimbursement Trends
- Manufacturers may adopt value-based pricing models.
- Payers push for discounts and prior authorization.
- Cost-sharing schemes could influence patient access, impacting overall revenue.
Regional Variations
| Region |
Price Range (USD) |
Market Penetration |
Reimbursement Landscape |
| U.S. |
65,000 |
High |
Complex, insurer-driven; discounts common |
| Europe |
50,000–65,000 |
Moderate |
National health systems negotiate prices |
| Asia |
30,000–45,000 |
Growing |
Limited coverage; pricing varies by country |
Regulatory Outlook
- U.S.: Ocrevus is fully approved with ongoing post-marketing surveillance.
- Europe: Approved since 2018; pricing negotiations ongoing.
- Emerging Markets: Approval trajectories vary; prices tend to be lower.
Key Takeaways
- The MS drug market trends favor continued growth for Ocrevus, driven by increasing prevalence and expanding indications.
- Sales are expected to grow annually through 2027, reaching USD 8.0 billion.
- Competition from biosimilars may reduce prices by 2026, impacting revenue.
- Pricing remains regionally variable, with U.S. prices averaging USD 65,000 per year.
- The landscape favors strategic partnerships, cost management, and innovation to sustain profitability.
FAQs
1. What is the primary therapeutic application of NDC 52427-0382?
Ocrevus treats relapsing and primary progressive multiple sclerosis by depleting B-cells.
2. How does Ocrevus's market share compare to competitors?
It accounts for approximately 12% of the MS drug market, second to Tecfidera.
3. What is the projected revenue trend for Ocrevus through 2027?
Revenues are projected to grow from USD 4.2 billion in 2022 to USD 8.0 billion by 2027, assuming incremental market share increases and expanded indications.
4. How could biosimilars impact Ocrevus’s pricing and revenue?
Biosimilars could enter by 2026, potentially decreasing prices by 20-30% and reducing revenue.
5. What factors influence regional pricing differences?
Healthcare system structures, negotiation power of payers, regulatory policies, and market competition impact regional pricing.
References
[1] IQVIA. (2023). Global Trends in Multiple Sclerosis Treatment. IQVIA Institute.
[2] MarketWatch. (2022). MS Drug Market Valuation & Forecasts.
[3] European Medicines Agency. (2018). Ocrelizumab Summary of Product Characteristics.
[4] U.S. Food and Drug Administration. (2017). Ocrevus (ocrelizumab) Approval Document.
[5] Statista. (2023). Multiple Sclerosis Market Data.
